Physician profile
Thomas Sasser
NPI 1174533814
$2,019.09
in general payments reported to CMS, 2019-2025
13 companies · $77.11 in 2025
The $77.11 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $12.93 · 2021: $15.06 · 2022: $1,438 · 2023: $38.06 · 2024: $270 · 2025: $77.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $385.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Team 1, LLC | $1,240.40 | 2022-2025 | |
| Miach Orthopaedics, INC. | $175.94 | 2024 | |
| Stryker Corporation | $175.00 | 2022 | |
| Vericel Corporation | $117.02 | 2019-2024 | Maci |
| Depuy Synthes Sales INC. | $104.85 | 2019-2024 | Orthovisc, Monovisc |
| Pacira Pharmaceuticals Incorporated | $42.66 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $41.82 | 2019-2022 | |
| Bioventus LLC | $27.29 | 2019-2024 | Durolane |
| Biocomposites INC | $24.46 | 2019-2025 | Stimulan |
| Innovation Technologies INC | $22.45 | 2023 | Irrisept |
| Averitas Pharma INC. | $16.28 | 2024 | Qutenza |
| Si-Bone, INC. | $15.61 | 2023 | |
| Molnlycke Health Care US, LLC | $15.31 | 2025 | Avance, Mepilex Border Post-Op |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Sasser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.